IP Library › Granted Patent US 12,533,414
Granted Patent B2
US 12,533,414 · App. 17/277,396 · Granted Jan 27, 2026

Protein L for activation and expansion of chimeric antigen receptor-modified immune cells

Inventors: Maksym Vodyanyk (Madison, WI); Ethan McLeod (Madison, WI); Xin Zhang (Madison, WI); Wen Bo Wang
Assignee: FUJIFILM Cellular Dynamics, Inc.
A61K45/06A61K40/11A61K40/31A61K40/4211A61P35/00C07K14/7051C07K14/70521C12N5/0636A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,414
App. No.
17/277,396
Granted
Jan 27, 2026
Kind
B2
Abstract

Provided herein are methods for the activation and expansion of T cells. Further provided are methods for the use of the T cells for therapy.

Claims (22)

1 . An in vitro method for activation and/or expansion of CAR-modified immune cells comprising:

(a) obtaining a starting population of induced pluripotent stem cell (iPSC)-derived CAR-modified immune cells; and

(b) culturing said population of CAR-modified immune cells on a culture surface coated with Protein L, Notch ligand DLL4, and recombinant fibronectin fragment rFN-CH-296 for a sufficient period of time to produce a population of activated and/or expanded CAR-modified immune cells.

2 . The method of claim 1 , wherein the culture surface is a culture plate, culture flask, microcarrier, microparticle, hydrogel particle, or culture bag.

3 . The method of claim 2 , wherein the culturing is performed in the absence of anti-CD3 antibody and/or antigen-specific target cells.

4 . The method of claim 1 , wherein the CAR-modified immune cells are T cells, NK cells, dendritic cells, and/or macrophages.

5 . The method of claim 4 , wherein the T cells are CD8 + T cells, CD4 + T cells, αβ T cells or γδ T cells.

6 . The method of claim 1 , wherein the iPSCs are reprogrammed from blood cells.

7 . The method of claim 1 , wherein the iPSCs are reprogrammed from T cells.

8 . The method of claim 1 , wherein the iPSCs are differentiated to CD34 + progenitors through cytokine-directed differentiation or forward programming.

9 . The method of claim 1 , wherein the culturing is performed in the presence of IL-2 and/or IL-15.

10 . The method of claim 1 , wherein the sufficient period of time is 8-12 days.

11 . The method of claim 1 , wherein the culturing is in medium comprising SCF, TPO, FLT3L, IL-7, and/or nicotinamide.

12 . The method of claim 1 , wherein the method results in the selective expansion of CAR-modified immune cells as compared to non-CAR-modified immune cells.

13 . The method of claim 12 , wherein at least 40% or 50% of the expanded population of CAR-modified immune cells are CAR-modified immune cells.

14 . The method of claim 4 , wherein the expanded population of CAR-modified T cells comprises 2-3 fold higher cytotoxic activity, increased IFNγ levels, and/or increased TNFα levels as compared to anti-CD3 expanded CAR-modified T cells.

15 . A population of activated and/or expanded CAR-modified immune cells produced according to the method of claim 1 .

16 . A method of treating a cancer in a subject comprising administering a therapeutically effective amount of the activated and/or expanded CAR-modified immune cells of claim 15 to the subject.

17 . The method of claim 1 , wherein the CAR-modified immune cells are macrophages.

18 . The method of claim 1 , wherein the CAR-modified immune cells are monocytes.

19 . The method of claim 1 , wherein the CAR-modified immune cells are T cells.

20 . The method of claim 1 , wherein the CAR-modified immune cells are B cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2021
From: VODYANYK, MAKSYM; MCLEOD, ETHAN; ZHANG, XIN; WANG, WEN BO
To: FUJIFILM CELLULAR DYNAMICS, INC.
Reel/Frame 057526/0989 →
Continuity (2)
Provisional Application 62733291 · Sep 19, 2018
Related Publication 20220031744A1 · Feb 3, 2022
References Cited (41)
US 8372642B2 · Rajesh et al. · 2013 [cited by applicant]
US 20100068192A1 · Enoki et al. · 2010 [cited by applicant]
US 20100279403A1 · Rajesh et al. · 2010 [cited by applicant]
US 20110027242A1 · Nukaya et al. · 2011 [cited by applicant]
US 20110158954A1 · Ideno et al. · 2011 [cited by applicant]
US 20230159891A1 · Kaneko et al. · 2023 [cited by applicant]
CN 102816734 · 2012 [cited by applicant]
CN 115516084 · 2022 [cited by applicant]
JP 2002535002 · 2002 [cited by applicant]
JP 2006516197 · 2006 [cited by applicant]
JP 2015521032 · 2015 [cited by applicant]
KR 1020180092951 · 2018 [cited by applicant]
WO WO2000044893 · 2000 [cited by applicant]
WO WO2004065590 · 2004 [cited by applicant]
WO WO2007040105 · 2007 [cited by applicant]
WO WO2008111430 · 2008 [cited by applicant]
WO WO2009119793 · 2009 [cited by applicant]
WO WO2013158856 · 2013 [cited by applicant]
WO WO2016164731A2 · 2016 [cited by examiner]
WO WO2017050428 · 2017 [cited by applicant]
WO WO2017070333 · 2017 [cited by applicant]
WO WO2017075389 · 2017 [cited by applicant]
WO WO2017079400 · 2017 [cited by applicant]
WO WO2017078807A1 · 2017 [cited by examiner]
WO WO2017161092 · 2017 [cited by applicant]
WO WO2018102795 · 2018 [cited by applicant]
Gurkan et al. (Tissue Engineering: Part A. 17(3):417-428. (2011)) (Year: 2011). [cited by examiner]
Zhang et al. Biomarker Research 5(22): 1-6. (2017) (Year: 2017). [cited by examiner]
Petrie et al. Biomaterials. 27:5459-5470 (2006) (Year: 2006). [cited by examiner]
Staunton et al. Preparation of recombinant fibronectin fragments for functional and structural studies. In: Even-Ram, S., Artym, V. (eds) Extracellular Matrix Protocols. Methods in Molecular Biology, vol. 522. Humana Pr… [cited by examiner]
Ku et al. Biomaterials. 26(25):5153-5157. (2005) (Year: 2005). [cited by examiner]
Office Action issued in Japanese Application No. 2021-515177, mailed Jul. 11, 2023. [cited by applicant]
Office Action issued in Japanese Application No. 2021-515177, mailed Mar. 19, 2024, and English translation thereof. [cited by applicant]
Lorenzo et al., “A B-cell superantigen induces the apoptosis of murine and human malignant B cells,” [cited by applicant]
PCT International Preliminary Report on Patentability issued in International Application No. PCT/US2019/051832, mailed Apr. 1, 2021. [cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/US2019/051832, mailed Dec. 4, 2019. [cited by applicant]
Walker et al., “Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase,” [cited by applicant]
Zheng et al., “Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry,” [cited by applicant]
Office Action issued in Chinese Application No. 201980061485.6, mailed Jun. 5, 2024, and English translation thereof. [cited by applicant]
Zhang, “Effect of D114-Notch signaling pathway blockade on development of Th17 cells in asthmatic mice,” [cited by applicant]
Office Action issued in Korean Application No. 10-2021-7011444, mailed Aug. 18, 2025, and English translation thereof. [cited by applicant]